← Leaderboards

Benjamin G. Neel

New York University School Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗

$33,134,772

Attributed

$38,464,312

Total exposure

24

Grants

13

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.2M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$71,454,151 · 25

By mechanism

P30$42,659,632 · 6

R01$21,979,679 · 9

R37$4,037,008 · 1

T32$1,479,705 · 1

P01$445,388 · 2

R21$435,827 · 1

Top collaborators

Most similar at New York University School Of Medicine

Same institution · by research overlap

Jane Amanda Skok$18,379,753
Dan R Littman$30,444,906
Kwok Kin Wong$31,472,345
Stevan R. Hubbard$8,441,812
Kelsey R Monson$170,583

Others in their field

Top investigators on “Malignant Neoplasms”

David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Richard K. Wilson · Washington University$274,272,747
Larry Arthur$223,443,122
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879

Research focus

Malignant NeoplasmsProgramsFundingCancer CenterCancer Center Support GrantResource SharingStrategic PlanningResearch PersonnelAnticancer ResearchMemberClinical TrialsFacultyBasePhenotypeAffectCellsLeadershipMutantPopulation SciencesInsightSignal TransductionAreaTranslational ResearchCaring

Grant awards (121)

Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$703,389

R01 · FY2025 · CA

New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$703,320

R01 · FY2025 · CA · contact PI

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$702,059

R01 · FY2025 · CA · contact PI

Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer$435,827

R21 · FY2025 · CA · contact PI

Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$668,222

R01 · FY2024 · CA

New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$668,154

R01 · FY2024 · CA · contact PI

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$666,956

R01 · FY2024 · CA · contact PI

Leadership, Planning and Evaluation$658,106

P30 · FY2024 · CA · contact PI

Developmental Funds$617,443

P30 · FY2024 · CA · contact PI

Developmental Funds$797,865

P30 · FY2023 · CA · contact PI

Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$689,321

R01 · FY2023 · CA

New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$689,255

R01 · FY2023 · CA · contact PI

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$688,018

R01 · FY2023 · CA · contact PI

Cancer Center Administration$482,046

P30 · FY2023 · CA · contact PI

Leadership, Planning and Evaluation$407,069

P30 · FY2023 · CA · contact PI

Cancer Center Support Grant$3,984,387

P30 · FY2022 · CA · contact PI

Developmental Funds$797,865

P30 · FY2022 · CA · contact PI

Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$702,264

R01 · FY2022 · CA

New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$689,255

R01 · FY2022 · CA · contact PI

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$688,018

R01 · FY2022 · CA · contact PI

Cancer Center Administration$482,046

P30 · FY2022 · CA · contact PI

Leadership, Planning and Evaluation$407,069

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant$211,875

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant$150,000

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant$61,247

P30 · FY2022 · CA · contact PI

Cancer Center Support Grant$3,984,387

P30 · FY2021 · CA · contact PI

Developmental Funds$797,865

P30 · FY2021 · CA · contact PI

New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$703,320

R01 · FY2021 · CA · contact PI

Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$703,176

R01 · FY2021 · CA · contact PI

Cancer Center Administration$482,046

P30 · FY2021 · CA · contact PI

Leadership, Planning and Evaluation$407,069

P30 · FY2021 · CA · contact PI

Cancer Center Support Grant$150,000

P30 · FY2021 · CA · contact PI

Cancer Center Support Grant$62,000

P30 · FY2021 · CA · contact PI

Cancer Center Support Grant$3,950,935

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$847,500

P30 · FY2020 · CA · contact PI

Developmental Funds$791,167

P30 · FY2020 · CA · contact PI

Signal Transduction by Non-Transmembrane PTPs$529,389

R01 · FY2020 · CA · contact PI

Cancer Center Administration$477,997

P30 · FY2020 · CA · contact PI

Leadership, Planning and Evaluation$403,652

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$200,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$190,645

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$150,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2020 · CA · contact PI

Cancer Center Support Grant$3,921,817

P30 · FY2019 · CA · contact PI

Developmental Funds$785,336

P30 · FY2019 · CA · contact PI

Signal Transduction by Non-Transmembrane PTPs$513,507

R01 · FY2019 · CA · contact PI

Cancer Center Administration$474,475

P30 · FY2019 · CA · contact PI

Leadership, Planning and Evaluation$400,677

P30 · FY2019 · CA · contact PI

Cancer Center Support Grant$125,000

P30 · FY2019 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2019 · CA · contact PI

Cancer Center Support Grant$2,636,133

P30 · FY2018 · CA · contact PI

Signal Transduction by Non-Transmembrane PTPs$529,389

R01 · FY2018 · CA · contact PI

Cancer Center Support Grant$2,636,133

P30 · FY2017 · CA · contact PI

Signal Transduction by Non-Transmembrane PTPs$529,389

R01 · FY2017 · CA · contact PI

Cancer Center Support Grant$368,033

P30 · FY2017 · CA · contact PI

Cancer Center Support Grant$118,219

P30 · FY2017 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2017 · CA · contact PI

Cancer Center Support Grant$2,549,235

P30 · FY2016 · CA · contact PI

Signal Transduction by Non-Transmembrane PTPs$529,389

R01 · FY2016 · CA · contact PI

Cancer Center Support Grant$121,609

P30 · FY2016 · CA · contact PI

Cancer Center Support Grant$60,000

P30 · FY2016 · CA · contact PI

Cancer Center Support Grant$2,436,664

P30 · FY2015 · CA · contact PI

Cancer Center Support Grant$611,572

P30 · FY2015 · CA · contact PI

Cancer Center Support Grant$68,490

P30 · FY2015 · CA · contact PI

Cancer Center Support Grant$43,749

P30 · FY2015 · CA · contact PI

Cancer Center Support Grant$2,352,696

P30 · FY2014 · CA · contact PI

Alternative tobacco products: Use adverse effects and communication patterns$607,764

P30 · FY2014 · CA · contact PI

The Ras/Mapk pathway in cardiovascular disease.$315,991

R01 · FY2014 · HL · contact PI

Cancer Center Support Grant$134,749

P30 · FY2014 · CA · contact PI

Cancer Center Support Grant$75,000

P30 · FY2014 · CA · contact PI

Signal Transduction by Non-transmembrane PTPs$311,658

R37 · FY2013 · CA · contact PI

The Ras/Mapk pathway in cardiovascular disease.$307,502

R01 · FY2013 · HL · contact PI

Signal Transduction by Non-transmembrane PTPs$332,791

R37 · FY2012 · CA · contact PI

The Ras/Mapk pathway in cardiovascular disease.$323,586

R01 · FY2012 · HL · contact PI

Signal Transduction by Non-transmembrane PTPs$334,064

R37 · FY2011 · CA · contact PI

The Ras/Mapk pathway in cardiovascular disease.$326,176

R01 · FY2011 · HL · contact PI

Signal Transduction by Non-transmembrane PTPs$344,692

R37 · FY2010 · CA · contact PI

Human Shp2 (Ptpn11) mutations and cardiac valve development$270,000

R01 · FY2010 · HL · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$263,240

R01 · FY2010 · CA · contact PI

Signal Transduction by Non-transmembrane PTPs$337,930

R37 · FY2009 · CA · contact PI

Human Shp2 (Ptpn11) mutations and cardiac valve development$270,000

R01 · FY2009 · HL · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$258,913

R01 · FY2009 · CA · contact PI

Human Shp2 (Ptpn11) mutations and cardiac valve development$425,000

R01 · FY2008 · HL · contact PI

Signal Transduction by Non-transmembrane PTPs$321,845

R37 · FY2008 · CA · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$317,087

R01 · FY2008 · CA · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$50,760

R01 · FY2008 · CA · contact PI

Signal Transduction by Non-transmembrane PTPs$502,926

R37 · FY2007 · CA · contact PI

Human Shp2 (Ptpn11) mutations and cardiac valve development$425,000

R01 · FY2007 · HL · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$394,394

R01 · FY2007 · CA · contact PI

Signal Transduction by Non-transmembrane PTPs$504,898

R37 · FY2006 · CA · contact PI

Role of Gab2 and Shp2 in Hematopoietic Signalling$394,842

R01 · FY2006 · CA · contact PI

EM LOCALIZATION OF PTP1B & RTK & PTP1B INTERACTIONS$2,039

P41 · FY2006 · RR · contact PI

Signal Transduction by Non-transmembrane PTPs$561,026

R37 · FY2005 · CA

Role of PTP1B in Body Mass Regulation$425,339

R01 · FY2005 · DK

EM LOCALIZATION OF PTP1B &RTK &PTP1B INTERACTIONS$216

P41 · FY2005 · RR

Signal Transduction by Non-transmembrane PTPs$485,178

R37 · FY2004 · CA

Role of PTP1B in Body Mass Regulation$412,975

R01 · FY2004 · DK

ROLE OF BAG2 AND SHP2 IN HEMATOPOIETIC SIGNALLING$412,380

R01 · FY2004 · DK

TRAINING PROGRAM IN CANCER BIOLOGY$266,899

T32 · FY2004 · CA

EM LOCALIZATION OF PTP1B &RTK &PTP1B INTERACTIONS$12,870

P41 · FY2004 · RR

SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPS$537,902

R01 · FY2003 · CA

ROLE OF BAG2 AND SHP2 IN HEMATOPOIETIC SIGNALLING$412,380

R01 · FY2003 · DK

Role of PTP1B in Body Mass Regulation$400,976

R01 · FY2003 · DK

TRAINING PROGRAM IN CANCER BIOLOGY$247,078

T32 · FY2003 · CA

SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPS$467,553

R01 · FY2002 · CA

ROLE OF BAG2 AND SHP2 IN HEMATOPOIETIC SIGNALLING$412,380

R01 · FY2002 · DK

Role of PTP1B in Body Mass Regulation$412,379

R01 · FY2002 · DK

TRAINING PROGRAM IN CANCER BIOLOGY$315,927

T32 · FY2002 · CA

2002 FASEB Meeting on Protein Phosphatases$8,000

R13 · FY2002 · CA

GAB2 AND SHP2 IN HEMATOPOIESIS AND LEUKEMOGENESIS$0

P01 · FY2002 · DK

ROLE OF BAG2 AND SHP2 IN HEMATOPOIETIC SIGNALLING$412,380

R01 · FY2001 · DK

SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPS$406,271

R01 · FY2001 · CA

TRAINING PROGRAM IN CANCER BIOLOGY$355,307

T32 · FY2001 · CA

HEMATOLOGIC DISEASES RESULTING FROM DEFECTS OF TYROSINE PHOSPHATASES$296,752

P01 · FY2001 · DK

ROLE OF PTPU AND SHPTP2 IN ENDOTHELIAL CELLS$274,326

P50 · FY2001 · HL

Molecular and Genetic Basis of Cell Proliferation$7,000

R13 · FY2001 · CA

SIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPS$396,774

R01 · FY2000 · CA

TRAINING PROGRAM IN CANCER BIOLOGY$294,494

T32 · FY2000 · CA

REGULATION OF B CELL SIGNALING BY SHPTP-1$231,709

R01 · FY2000 · CA

HEMATOLOGIC DISEASES RESULTING FROM DEFECTS OF TYROSINE PHOSPHATASES$148,636

P01 · FY2000 · DK

ROLE OF PTPU AND SHPTP2 IN ENDOTHELIAL CELLS$112,461

P50 · FY2000 · HL